Teva Stock Falls After COVID-19 Impacts Q2 Top And Bottomline; Lowers FY21 Outlook
July 28, 2021 at 11:38 AM EDT
Teva Pharmaceutical Industries Ltd Q2 sales reached $3.9 billion, increasing 1% Y/Y or decreasing 2% in local currency terms, missing the consensus of $4.04 billion.
